NLRP3 and colorectal carcinoma: Additionally, ChIP with a p‐P65 antibody demonstrated that p‐P65 occupancy at the NLRP3 promoter decreased after BRD4 siRNA treatment inhibition in HDAC2 KO CRC cells (Figure 6G).